跳至主要内容
临床试验/NCT01876121
NCT01876121已完成不适用

Celecoxib Japan Observational Study for the Patients With Acute Pain

Astellas Pharma Inc0 个研究点目标入组 784 人开始时间: 2012年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
784
主要终点
Safety assessed by the incidence of adverse events and lab-tests

研究概览

简要总结

This study is to assess the safety and efficacy of celecoxib on the pain relief from acute pain.

详细描述

Patients with traumatic pain, post-surgical and tooth extract pain will be included in this study. Patients will receive Celecoxib for 2 weeks and the efficacy on pain relief and the safety will be evaluated.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with traumatic pain, post-surgical pain and tooth extract pain

排除标准

  • Hyperreactive to sulfonamide
  • Aspirin asthma patients
  • Peptidic ulcer patients
  • Serious liver disease patients
  • Serious kidney disease patients
  • Serious heart failure patients
  • End of pregnancy

研究组 & 干预措施

Celecox group

干预措施: Celecoxib (Drug)

结局指标

主要结局

Safety assessed by the incidence of adverse events and lab-tests

时间窗: For 2 weeks

次要结局

  • Overall pain improvement assessed by visual analogue scale (VAS)(Baseline and week-2)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验